Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Mexico for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Mexico only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Mexico (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Amyn Alidina (NPI 1821088063)

Field	Value
Entity Type	Individual
Organization	Amyn Alidina
Address	4901 Lang Ave Ne
City	Albuquerque
State	NM
ZIP	87109
Taxonomy	Medical Oncology Physician
NPI Enumerated	October 27, 2005

Payer Source	Total Paid
Medicare	$785K
Medicaid	$0

Key Findings

AMYN ALIDINA is a Medical Oncology Physician in ALBUQUERQUE, NM with lifetime Medicare revenue of $785K and no Medicaid billing on file, making the provider effectively single‑payer (Medicare) in the available claims data. The provider’s NPI was enumerated 2005-10-27 (~21 years ago), indicating a long-tenured practice presence in the market.

Revenue is highly concentrated: the precomputed top three Medicare codes account for 69.9% of this provider's total Medicare revenue, driven primarily by J9271 (42.7% of total Medicare revenue), J0897 (14.1%), and 99215 (13.0%). This concentration indicates a small set of services dominate billing and revenue streams.

The code mix points to a practice centered on systemic oncology care and infusion services: J9271 (injection, pembrolizumab) appears as the single largest revenue driver with 7.6K claims and $326.8K revenue, and J0897 (denosumab) contributes 6K claims and $108K revenue. Chemotherapy administration codes such as 96413 (317 claims, $30.4K) and multiple add‑on infusion codes are also present, supporting the interpretation that infusion and oncology drug administration are core operations.

High‑complexity office visits are a distinctive feature of this provider’s Medicare profile: 99215 accounts for $99.5K revenue across 771 claims and is labeled an "extreme outlier," ranking #602 of 145531 providers nationally (100th percentile). This suggests the provider bills an unusually large volume of high‑level established patient E/M encounters compared with national peers, consistent with management of complex oncology patients.

Competitive standing is mixed by service line: for J9271 the provider ranks #1458 of 1841 (20th percentile), a typical/ unremarkable national position for pembrolizumab administration, while for supportive device care the provider shows stronger relative activity—96523 (irrigation of venous access device) ranks #88 of 1643 (95th percentile), categorized as notably above typical national volume. In short, the practice is not a national leader in biologic drug administration volume but is comparatively more active in procedural device maintenance.

Operational signals from utilization detail include very high claim counts but low per‑claim payments for some unit‑priced drugs: J1439 reports 37.5K claims at $1 avg paid/claim totaling $37.5K, and J0881 reports 14K claims at $2 avg paid/claim totaling $28K. These patterns suggest substantial unit‑based drug billing (many small units) alongside higher‑value biologic infusions, which has implications for infusion center throughput and inventory management.

Ancillary services such as radiation delivery appear in the mix but represent small shares of revenue: G6015 contributes $19.1K (2.5% of Medicare revenue) and G6012 contributes $5K (0.7%), both ranked in the lower percentiles nationally. This indicates limited or occasional radiation treatment delivery activity relative to the provider’s dominant infusion and office E/M services.

For payer strategy and network assessment, the absence of any Medicaid billing on file combined with $785K in Medicare revenue highlights Medicare dependence for public payer volume; absence of Medicaid activity may reflect contracting choices, patient mix, or administrative routing to other group providers. Analysts should treat this profile as a Medicare‑centric oncology practice with concentrated revenue drivers and a notable emphasis on high‑complexity office visits.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

50 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	7,600	$40	$326.8K
J0897	Injection, denosumab, 1 mg	6,000	$20	$108K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	770	$130	$99.5K
J1439	Injection, ferric carboxymaltose, 1 mg	37,500	$1	$37.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	320	$100	$30.4K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	220	$130	$29.2K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	14,010	$1	$28K
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session	70	$260	$19.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	190	$90	$16.5K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	50	$160	$8.5K

Showing 1–10 of 50

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 50 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Mexico Distribution

Amyn Alidina — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Mexico

Full comparison — all codes billed, vs. state median

50 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	10	9,400	$40	$469.6K
J0897	11	50	3,150	$20	$113.2K
G6015	4	10	70	$260	$49.4K
J0881	2	10	12,320	$1	$31.2K
J9217	6	20	180	$130	$23.4K
J1439	3	10	25,500	$1	$23.1K
96413	6	40	170	$90	$17.7K
J3490	16	20	40	$150	$16.7K
G6012	5	10	80	$170	$16.5K
99214	744	2,700	90	$70	$12.9K

Showing 1–10 of 50

Related Providers

Other providers that share a Tax Identification Number (TIN) with Amyn Alidina, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
New Mexico Oncology Hematology Consultants, Ltd.	NM	Hematology & Oncology Physician	$0	$4.2M
Gregg Franklin	NM	Radiation Oncology Physician	$2.5M	$0
Scott Stoerner	NM	Rheumatology Physician	$1.5M	$0
Shaya Ansari	NY	Diagnostic Radiology Physician	$1.5M	$1K
Pranshu Bansal	AZ	Hematology & Oncology Physician	$1.4M	$0
Ronald Kubica	NM	Medical Oncology Physician	$1M	$0
Annette Fontaine	NM	Medical Oncology Physician	$918.5K	$0
Mrunal Tailor	NM	Diagnostic Radiology Physician	$897.5K	$0
Jose Avitia	NM	Hematology & Oncology Physician	$880.2K	$0
Masoud Shiehmorteza	NM	Diagnostic Radiology Physician	$773.7K	$0

Nearby Providers

Other providers in the same ZIP code as Amyn Alidina, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Presbyterian Healthcare Services	NM	Internal Medicine Physician	$0	$240.8M
Heritage Home Healthcare Services, Inc.	NM	Home Health Agency	$0	$141.5M
Home Medical Equipment Specialists LLC	NM	Durable Medical Equipment & Medical Supplies	$0	$100M
The New Beginnings LLC	NM	Adult Day Care Clinic/Center	$0	$85.1M
We Care Agency, Inc.	NM	In Home Supportive Care Agency	$0	$60.1M
Lovelace Health System, LLC	NM	General Acute Care Hospital	$0	$57.7M
Adelante Development Center, Inc.	NM	Personal Care Attendant	$0	$57M
Eye Associates Of New Mexico Ltd	NM	Ophthalmology Physician	$0	$46.9M
Southwest Labs LLC	NM	Clinical Medical Laboratory	$1.1M	$41.5M
Southwest Medical Associates, LLC	NM	General Practice Physician	$0	$41.4M

Amyn Alidina — Billing Profile & Reimbursement Data

Sign up for Amyn Alidina — Billing Profile & Reimbursement Data policy alerts

Amyn Alidina — Billing Profile & Reimbursement Data

Sign up for Amyn Alidina — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References